ALLUVI: A THOROUGH EXPLORATION INTO THE MEDICATION'S POTENTIAL

Alluvi, initially dubbed LY3414901, represents a noteworthy advancement in weight management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist exhibits remarkable efficacy in early trial data, with substantial weight loss